Lionheart Health Patents Bioelectric System to Boost Regenerative Proteins

Lionheart Health, Inc., in collaboration with Leonhardt Ventures LLC, has achieved a significant breakthrough in regenerative medicine by securing a Letter of Allowance from the United States Patent and Trademark Office for its innovative bioelectric stimulation system. The patent, titled "Modulation of Growth Differentiation Factor 10 (GDF10) and BDNF," covers a low-voltage, pulsed technology designed to upregulate key regenerative proteins—specifically GDF10 and Brain Derived Neurotrophic Factor (BDNF)—in target tissues without systemic drug exposure. Inventors Howard J. Leonhardt and neuroscientist Kelsie Leonhardt developed this system, which operates at 2 mA to 4 mA direct current positive polarity, with optimized stimulation at approximately 3 mA, and also enhances complementary proteins like Klotho, stromal cell-derived factor 1 (SDF1), and insulin-like growth factor 1 (IGF-1). This advancement is part of Lionheart Health's broader mission to harness bioelectric signaling for activating the body's innate repair mechanisms, potentially revolutionizing treatments for neurological and other health conditions.

The company has validated its technology through rigorous pre-clinical and pilot clinical studies, including animal models at AccuLab Life Sciences with support from a University of California Irvine Capstone Research Grant, and a human pilot study in Brazil using its Brain Band™ platform. These studies demonstrated measurable modulation of regenerative pathways, activation of neuroplasticity-related proteins, and functional improvements in cognition, memory, mood, and depression symptoms among participants. The Brain Band™ programming, which includes protocols like DepressiStim™ and MemoryStim™, is part of Lionheart Health's KLOTHO-UP Study, currently competing in the Semi-Finals of the $101 million XPRIZE Healthspan competition. This validation underscores the potential of non-invasive bioelectric modulation to address a wide range of health issues, from stroke rehabilitation to broader healthspan optimization, as highlighted by Howard J. Leonhardt, who emphasized the milestone's importance in accelerating recovery and supporting longevity.

Investigational applications of the patented technology span multiple health domains, including neurological and brain health (e.g., stroke rehabilitation, Alzheimer's and Parkinson's diseases), muscle and mobility health (e.g., post-stroke motor recovery, sarcopenia mitigation), immune and regenerative resilience, vascular and circulatory health, and liver and metabolic health. The patent also targets additional tissues such as the retina, cochlea, and bone, positioning Lionheart Health as a leader in bioelectric regenerative medicine. This patent allowance strengthens the company's intellectual property portfolio and supports its multi-protein regenerative platform strategy, which includes technologies like Brain Band™, BodStim™, and OrthoStim™. For more information, visit www.LionheartLongevity.com, www.LionheartHealthStim.com, and www.LeonhardtVentures.com, where the company outlines its commitment to advancing clinical research for functional healthspan endpoints like mobility and cognition, though these technologies remain investigational and not FDA-approved for specific diseases.